Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
Phase 1
- Conditions
- Gastrointestinal CancerBile Duct CarcinomaEsophageal CarcinomaColorectal AdenocarcinomaGastric AdenocarcinomaPancreatic AdenocarcinomaHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2018-04-25
- Last Posted Date
- 2020-07-24
- Lead Sponsor
- Curegenix Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT03507998
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
🇨🇳Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Phase 1
- Conditions
- Solid TumorsGI Cancer
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- Curegenix Inc.
- Target Recruit Count
- 72
- Registration Number
- NCT02675946
- Locations
- 🇺🇸
Edward H. Kaplan MD and Associates, Skokie, Illinois, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Care, Long Beach, California, United States
© Copyright 2025. All Rights Reserved by MedPath